disodium;2-[2-[carboxylatomethyl-[2-oxo-2-[(2R,3S,4R,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]oxyethyl]amino]ethyl-(carboxymethyl)amino]acetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: disodium;2-[2-[carboxylatomethyl-[2-oxo-2-[(2R,3S,4R,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]oxyethyl]amino]ethyl-(carboxymethyl)amino]acetate
• 化学式: C16H24N2Na2O13
• 分子量: 498.35
• InChiKey: GFYMTJLIOMTFEQ-NQRKUMERSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -13.63
• 重原子数：
  33
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  248
• 氢给体数：
  5
• 氢受体数：
  15

文献信息

• COMBINATION OF LEVOCABASTINE AND FLUTICASONE FUROATE FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC CONDITIONS
  申请人：Glaxo Group Limited

  公开号：EP2931249A1

  公开（公告）日：2015-10-21
• [EN] COMBINATION OF LEVOCABASTINE AND FLUTICASONE FUROATE FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC CONDITIONS<br/>[FR] COMBINAISON DE LÉVOCABASTINE ET DE FUROATE DE FLUTICASONE DESTINÉE AU TRAITEMENT D'ÉTATS INFLAMMATOIRES ET/OU ALLERGIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2014095602A1

  公开（公告）日：2014-06-26

  The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of the androstane series and levocabastine, an H1 antagonist/anti-allergic. The present invention also relates to therapeutic uses thereof, particularly for the treatment of inflammatory and allergic conditions, specifically rhinitis.